Capless-saRNA: A Patent-Free, Cost-Efficient RNA Vaccine Platform

We’ve developed a novel Capless self-amplifying RNA (saRNA) platform that avoids global mRNA vaccine patents by removing the need for 5' capping and modified nucleotides. It delivers high antigen expression with low RNA doses, significantly reducing manufacturing costs.

Technology Details

[Proprietary Next-Generation Capless Self-Amplifying RNA Platform

In collaboration with a domestic partner, we've also applied a next-gen LNP optimized for Capless-saRNA, enhancing delivery efficiency and minimizing DDS risks. This platform enables rapid, scalable development of vaccines and RNA therapeutics across infectious diseases and cancer.

Problem & Unmet Needs

Private

Market Trends

Vaccine market size

- Our primary focus areas—infectious diseases and oncology— are experiencing rapid growth, driven by a surge in clinical trials and global demand. The global vaccine market, valued at $39.6B in 2019, is projected to reach $103.5B by 2028, with mRNA-based vaccines leading the expansion. - We are actively collaborating with domestic partners to apply next-generation LNP (lipid nanoparticle) delivery technologies, minimizing DDS-related risks and enhancing product competitiveness.

Competitive Landscape

Key Differentistors

- MicroUNI has developed a proprietary Capless-saRNA platform that dramatically improves both efficiency and costeffectiveness. - This breakthrough technology increases protein expression by more than tenfold compared to traditional mRNA methods, delivering exceptional results even with lower vaccine doses. By eliminating the expensive capping step and the need for modified UTPs, MicroUNI not only sidesteps existing patent barriers but also significantly reduces vaccine production costs